Newsfeeds - Spark Newswire

1 minute read

RxSight Q2 Adj. EPS $(0.50) Beats $(0.69) Estimate, Sales $11.36M Beat $10.75M Estimate

Today, 12:16 PM

RxSight (NASDAQ:RXST) reported quarterly losses of $(0.50) per share which beat the analyst consensus estimate of $(0.69) by 27.54 percent. This is a 84.57 percent increase over losses of $(3.24) per share from the same

RXST

1 minute read

Movers

12 Health Care Stocks Moving In Monday’s After-Market Session

By Benzinga Insights

Today, 12:16 PM

Gainers Novo Integrated Sciences (NASDAQ:NVOS) shares increased by 21.7% to $2.3 during Monday's after-market session. The market value of their outstanding shares is at $68.8 million.

ADIL

5 minute read

67 Biggest Movers From Yesterday

By Lisa Levin

Today, 12:16 PM

Gainers Convey Health Solutions Holdings, Inc. (NYSE: CNVY) shares jumped 138.4% to close at $10.30 as the company agreed to be taken private by TPG Capital.

ACAD

4 minute read

55 Stocks Moving In Friday’s Mid-Day Session

By Lisa Levin

Today, 12:16 PM

Gainers Swvl Holdings Corp. (NASDAQ: SWVL) surged 24.4% to $7.50. Swvl Holdings 13D Filing from investor Ahmed Sabbah showed a new 6.4% stake in the company.

AOSL

30 minute read

Earnings Scheduled For May 5, 2022

By Benzinga Insights

Today, 12:16 PM

Companies Reporting Before The Bell • Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.

AAOI

2 minute read

RxSight Highlights Presentations For Its Light Adjustable Lens System At American Society Of Cataract, Refractive Surgery Meeting Apr. 22-25

By Benzinga Newsdesk

Today, 12:16 PM

(NASDAQ:RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today announced that its Light Adjustable Lens system, comprised of the

RXST

12 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For April 8, 2022

By Benzinga Insights

Today, 12:16 PM

Upgrades

1 minute read

Needham Initiates Coverage On RxSight with Buy Rating, Announces Price Target of $18

By Benzinga Newsdesk

Today, 12:16 PM

Needham analyst David Saxon initiates coverage on RxSight (NASDAQ:RXST) with a Buy rating and announces Price Target of $18.

RXST

2 minute read

Earnings

RxSight’s Return On Capital Employed Insights

By Benzinga Insights

Today, 12:16 PM

Benzinga Pro data, RxSight (NASDAQ:RXST) reported Q4 sales of $8.43 million. Earnings fell to a loss of $15.73 million, resulting in a 24.15% decrease from last quarter.

RXST

6 minute read

Earnings Scheduled For March 8, 2022

By Benzinga Insights

Today, 12:16 PM

Companies Reporting Before The Bell • Babcock & Wilcox (NYSE:BW) is likely to report quarterly earnings at $0.10 per share on revenue of $196.62 million.

ABM